Home8QQ • FRA
add
AbCellera Biologics Inc
Previous close
€2.30
Day range
€2.31 - €2.34
Year range
€2.17 - €5.43
Market cap
813.47M USD
Avg Volume
159.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 7.32M | -27.18% |
Operating expense | 59.85M | 139.67% |
Net income | -36.93M | -20.97% |
Net profit margin | -504.30 | -66.12% |
Earnings per share | -0.13 | -18.18% |
EBITDA | -56.93M | -24.36% |
Effective tax rate | 23.36% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 670.36M | -15.75% |
Total assets | 1.41B | -8.11% |
Total liabilities | 301.51M | -11.93% |
Total equity | 1.11B | — |
Shares outstanding | 294.67M | — |
Price to book | 0.61 | — |
Return on assets | -16.25% | — |
Return on capital | -19.58% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -36.93M | -20.97% |
Cash from operations | -29.97M | -250.56% |
Cash from investing | 52.10M | 251.49% |
Cash from financing | 2.65M | 532.70% |
Net change in cash | 24.74M | 286.42% |
Free cash flow | -42.55M | -1,686.49% |
About
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
CEO
Founded
2012
Headquarters
Website
Employees
586
